ECSP045029A - Composiciones de valdecoxib de disgregación intraoral - Google Patents
Composiciones de valdecoxib de disgregación intraoralInfo
- Publication number
- ECSP045029A ECSP045029A EC2004005029A ECSP045029A ECSP045029A EC SP045029 A ECSP045029 A EC SP045029A EC 2004005029 A EC2004005029 A EC 2004005029A EC SP045029 A ECSP045029 A EC SP045029A EC SP045029 A ECSP045029 A EC SP045029A
- Authority
- EC
- Ecuador
- Prior art keywords
- compositions
- intraoral
- disgregation
- valdecoxib
- valdecoxib compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002004 valdecoxib Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32535601P | 2001-09-26 | 2001-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045029A true ECSP045029A (es) | 2004-04-28 |
Family
ID=23267542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005029A ECSP045029A (es) | 2001-09-26 | 2004-03-23 | Composiciones de valdecoxib de disgregación intraoral |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20030181501A1 (https=) |
| EP (2) | EP1490035A1 (https=) |
| JP (2) | JP2005506987A (https=) |
| KR (2) | KR20040044990A (https=) |
| CN (2) | CN1633281A (https=) |
| AP (2) | AP2004002999A0 (https=) |
| AR (1) | AR037239A1 (https=) |
| BR (2) | BR0212861A (https=) |
| CA (2) | CA2461044A1 (https=) |
| CO (2) | CO5570684A2 (https=) |
| EA (2) | EA200400352A1 (https=) |
| EC (1) | ECSP045029A (https=) |
| GE (1) | GEP20063856B (https=) |
| HK (1) | HK1079988A1 (https=) |
| IL (2) | IL160855A0 (https=) |
| IS (2) | IS7178A (https=) |
| MA (2) | MA27682A1 (https=) |
| MX (2) | MXPA04002798A (https=) |
| NO (2) | NO20041258L (https=) |
| OA (2) | OA12707A (https=) |
| PL (2) | PL369298A1 (https=) |
| TN (2) | TNSN04045A1 (https=) |
| WO (2) | WO2003026623A1 (https=) |
| YU (1) | YU34804A (https=) |
| ZA (2) | ZA200401953B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005002557A1 (en) * | 2003-07-03 | 2005-01-13 | Warner-Lambert Company Llc | Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof |
| US20050186271A1 (en) * | 2004-02-24 | 2005-08-25 | Sheskey Paul J. | Process for dispersing a fluid in a mass of solid particles |
| WO2006016602A1 (ja) * | 2004-08-10 | 2006-02-16 | Ajinomoto Co., Inc. | 苦味の低減したナテグリニド含有製剤 |
| US20080063710A1 (en) * | 2004-12-28 | 2008-03-13 | Eisai R&D Management Co., Ltd. | Rapidly Disintegrating Tablet and Production Method Thereof |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| EP1964549A1 (en) * | 2005-12-20 | 2008-09-03 | Eisai R&D Management Co., Ltd. | Orally disintegrating tablet comprising fat-soluble substance |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| WO2007087188A2 (en) * | 2006-01-20 | 2007-08-02 | Merck & Co., Inc. | Taste-masked tablets and granules |
| US20070196494A1 (en) * | 2006-02-17 | 2007-08-23 | Arnaud Grenier | Low-friability, patient-friendly orally disintegrating formulations |
| JP2009537554A (ja) * | 2006-05-19 | 2009-10-29 | ソマクソン ファーマシューティカルズ インコーポレイテッド | 不眠症を治療するための、口腔内、舌下および急速融解製剤を含む、低用量ドキセピン製剤、ならびにその使用 |
| US8685457B2 (en) * | 2007-06-06 | 2014-04-01 | Basf Se | Pharmaceutical formulation for the production of rapidly disintegrating tablets |
| CN102083410B (zh) * | 2007-06-06 | 2013-04-17 | 巴斯夫欧洲公司 | 用于制备迅速崩解的片剂的药物制剂 |
| JP2010529073A (ja) * | 2007-06-06 | 2010-08-26 | ビーエーエスエフ ソシエタス・ヨーロピア | チュアブル錠及びトローチ剤製造のための医薬製剤 |
| KR20160083132A (ko) * | 2007-06-06 | 2016-07-11 | 바스프 에스이 | 급속 붕해 정제의 제조를 위한 제약 제제 |
| CN101820838B (zh) * | 2007-08-07 | 2013-06-05 | 阿塞尔Rx制药有限公司 | 采用口腔经粘膜剂型的用于程序镇静和镇痛的组合物和方法 |
| EP2268268A2 (en) * | 2008-03-24 | 2011-01-05 | Wockhardt Research Centre | Orally disintegrating compositions of rhein or diacerein |
| US8945592B2 (en) * | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| CN102223880B (zh) * | 2008-11-25 | 2017-04-26 | 田边三菱制药株式会社 | 口腔速崩片及其制备方法 |
| US20110097401A1 (en) | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| US20110091544A1 (en) * | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
| FR2968995B1 (fr) * | 2010-12-16 | 2013-03-22 | Sanofi Aventis | Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage |
| CN106822007B (zh) | 2015-09-11 | 2021-12-31 | 西姆莱斯股份公司 | 口服制剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| SK74396A3 (en) * | 1995-06-13 | 1997-04-09 | American Home Prod | Organoleptically acceptable oral pharmaceutical compositions |
| JPH11513641A (ja) * | 1995-10-20 | 1999-11-24 | ファルマシア・アンド・アップジョン・カンパニー | ブリスターパッケージ |
| CN1140267C (zh) * | 1996-05-17 | 2004-03-03 | 麦克公司 | 治疗环加氧酶-2介导的疾病的每天一次的组合物 |
| EP0863134A1 (en) * | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2 |
| US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
| JP2003516353A (ja) * | 1999-12-08 | 2003-05-13 | ファルマシア コーポレイション | ヴァルデコキシブ組成物 |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US6800297B2 (en) * | 2000-06-15 | 2004-10-05 | Acusphere, Inc. | Porous COX-2 inhibitor matrices and methods of manufacture thereof |
| CN1638739A (zh) * | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| JP2004506680A (ja) * | 2000-08-18 | 2004-03-04 | ファルマシア・コーポレーション | シクロオキシゲナーゼ−２阻害剤の迅速崩壊経口製剤 |
-
2002
- 2002-09-23 MX MXPA04002798A patent/MXPA04002798A/es unknown
- 2002-09-23 HK HK06100055.6A patent/HK1079988A1/zh unknown
- 2002-09-23 OA OA1200400083A patent/OA12707A/en unknown
- 2002-09-23 IL IL16085502A patent/IL160855A0/xx unknown
- 2002-09-23 BR BR0212861-6A patent/BR0212861A/pt not_active IP Right Cessation
- 2002-09-23 EA EA200400352A patent/EA200400352A1/ru unknown
- 2002-09-23 AP APAP/P/2004/002999A patent/AP2004002999A0/en unknown
- 2002-09-23 PL PL02369298A patent/PL369298A1/xx not_active Application Discontinuation
- 2002-09-23 OA OA1200400082A patent/OA13060A/en unknown
- 2002-09-23 CN CNA028211413A patent/CN1633281A/zh active Pending
- 2002-09-23 KR KR10-2004-7004373A patent/KR20040044990A/ko not_active Ceased
- 2002-09-23 BR BR0212778-4A patent/BR0212778A/pt not_active IP Right Cessation
- 2002-09-23 WO PCT/US2002/030161 patent/WO2003026623A1/en not_active Ceased
- 2002-09-23 CA CA002461044A patent/CA2461044A1/en not_active Abandoned
- 2002-09-23 AP APAP/P/2004/002998A patent/AP2004002998A0/en unknown
- 2002-09-23 CA CA002461630A patent/CA2461630A1/en not_active Abandoned
- 2002-09-23 PL PL02369297A patent/PL369297A1/xx not_active Application Discontinuation
- 2002-09-23 WO PCT/US2002/030048 patent/WO2003026697A2/en not_active Ceased
- 2002-09-23 EP EP02775948A patent/EP1490035A1/en not_active Withdrawn
- 2002-09-23 KR KR10-2004-7004334A patent/KR20040058189A/ko not_active Ceased
- 2002-09-23 YU YU34804A patent/YU34804A/sh unknown
- 2002-09-23 GE GE5525A patent/GEP20063856B/en unknown
- 2002-09-23 MX MXPA04002652A patent/MXPA04002652A/es unknown
- 2002-09-23 CN CNA028189078A patent/CN1703203A/zh active Pending
- 2002-09-23 JP JP2003530331A patent/JP2005506987A/ja not_active Withdrawn
- 2002-09-23 IL IL16084802A patent/IL160848A0/xx unknown
- 2002-09-23 EA EA200400357A patent/EA200400357A1/ru unknown
- 2002-09-23 JP JP2003530260A patent/JP2005512964A/ja not_active Withdrawn
- 2002-09-23 US US10/252,222 patent/US20030181501A1/en not_active Abandoned
- 2002-09-23 EP EP02773522A patent/EP1429736A2/en not_active Withdrawn
- 2002-09-26 AR ARP020103627A patent/AR037239A1/es unknown
-
2004
- 2004-03-10 ZA ZA200401953A patent/ZA200401953B/en unknown
- 2004-03-11 IS IS7178A patent/IS7178A/is unknown
- 2004-03-11 IS IS7177A patent/IS7177A/is unknown
- 2004-03-23 TN TNP2004000045A patent/TNSN04045A1/fr unknown
- 2004-03-23 EC EC2004005029A patent/ECSP045029A/es unknown
- 2004-03-24 MA MA27586A patent/MA27682A1/fr unknown
- 2004-03-24 TN TNP2004000047A patent/TNSN04047A1/fr unknown
- 2004-03-24 MA MA27587A patent/MA27542A1/fr unknown
- 2004-03-25 NO NO20041258A patent/NO20041258L/no not_active Application Discontinuation
- 2004-03-25 ZA ZA200402364A patent/ZA200402364B/xx unknown
- 2004-03-26 CO CO04028409A patent/CO5570684A2/es not_active Application Discontinuation
- 2004-03-26 CO CO04028410A patent/CO5570659A2/es not_active Application Discontinuation
- 2004-04-15 NO NO20041532A patent/NO20041532L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045029A (es) | Composiciones de valdecoxib de disgregación intraoral | |
| NO20076508L (no) | Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav | |
| EP1558220A4 (en) | ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
| NZ591873A (en) | Co-crystals of tramadol and nsaids | |
| EP4327888A3 (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
| NO20064041L (no) | Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter | |
| SE0300831D0 (sv) | New formulations and use therof | |
| WO2008116890A3 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
| CO6270217A2 (es) | Formulaciones galenicas de alisquireno y valsartan | |
| FR2878161B1 (fr) | Forme medicamenteuse orale, solide et concue pour eviter le mesusage | |
| PT1383752E (pt) | 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos | |
| EA200702522A1 (ru) | Система доставки лекарств в полость рта и способы ее применения | |
| UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
| WO2007144080A3 (de) | Antidepressiva-kombinations-wafer | |
| MXPA05008843A (es) | Sistema terapeutico que comprende amoxicilina y acido clavulanico. | |
| ECSP045056A (es) | Composiciones de valdecoxib de disgregación intraoral preparadas mediante un procedimiento de desecación por pulverizacion | |
| BR112015010808A2 (pt) | pastilha medicamentosa à base de ibuprofeno sódico di-hidratado | |
| BRPI0516545A (pt) | uso de óleo de lavanda para a profilaxia e tratamento de neurastenia, distúrbios de somatização e outras doenças associadas ao estresse | |
| CR7289A (es) | Composiciones de valdecoxib de disgregacion intraoral | |
| TR200900880A2 (tr) | Tek bir dozaj formunda kombine edilen farmasötik bileşimler. | |
| MX2022014198A (es) | Usos y formulaciones de los cannabinoides. |